Welcome to our dedicated page for American Well SEC filings (Ticker: AMWL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on American Well's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into American Well's regulatory disclosures and financial reporting.
American Well Corporation affiliate submitted a Form 144 notice reporting proposed and recent transactions in Class A Common Stock. The notice lists 6,786 shares tied to the vesting of a Restricted Stock Unit grant dated 06/01/2026. It also records prior dispositions of 3,706 shares on 04/01/2026 and 3,573 shares on 03/02/2026 by Phyllis Gotlib.
American Well Corp: Senvest Management, LLC and Richard Mashaal reported beneficial ownership of 1,136,558 shares of Class A Common Stock, representing 7.6% of the class. The percentage is calculated using 14,904,513 shares outstanding as of January 30, 2026, per the company's Form 10-K.
Those shares are held in accounts for Senvest Master Fund, LP and Senvest Technology Partners Master Fund, LP; Senvest Management, LLC and Mr. Mashaal report shared voting and shared dispositive power over the reported shares.
American Well Corporation reports that co-founder Dr. Roy Schoenberg has resigned from its Board of Directors, effective May 6, 2026. The company explains that he is leaving in connection with a new employment opportunity.
His resignation is described as not resulting from any disagreement with American Well on operations, policies, or procedures. The company highlights his nearly twenty years of leadership, including service as Executive Vice Chairman of the Board, and credits him with a lasting impact on its growth and evolution.
American Well Corp director and co-CEO Ido Schoenberg reported a small open-market share purchase. On May 7, 2026, he bought 670 shares of Class A Common Stock at $7.37 per share in an open-market transaction, increasing his direct holdings to 114,920 shares. The filing also shows indirect ownership of 163,004 shares held by his wife.
American Well Corp (AMWL) Schedule 13G/A amendment reports beneficial ownership by Morgan Stanley entities. The filing shows shared voting power of 1,155,379 and shared dispositive power of 1,156,087 for Morgan Stanley; Morgan Stanley Capital Services LLC shows 1,144,003 shared voting and dispositive power. The filing lists 7.8% and 7.7% of the Class A Common Stock for the respective reporting units and includes exhibits: a joint filing agreement and Item 7 subsidiary information.
American Well Corporation reported a smaller loss in Q1 2026 as cost cuts offset lower revenue. Revenue was $54.9 million, down 18% from $66.8 million a year ago, mainly from lower platform subscription and services revenue. Visit revenue rose to $28.9 million as more activity shifted to special program visits, with about 1.1 million total visits on the Amwell Platform.
Operating loss narrowed to $17.4 million from $30.4 million, helped by sharp reductions in research and development, sales and marketing, and general and administrative expenses after headcount cuts and other savings. Net loss attributable to Amwell improved to $10.9 million, or $(0.66) per share, from $(1.19) per share a year earlier. Adjusted EBITDA was a loss of $3.1 million, better than a $12.2 million loss in Q1 2025.
The company recorded a $7.0 million gain from contingent consideration tied to its prior APC divestiture and a $3.4 million impairment from abandoning its corporate headquarters lease. Amwell ended the quarter with $179.2 million in cash and cash equivalents, no debt, and used only $1.0 million of cash in operating activities.
American Well Corporation reported first quarter 2026 results with shrinking losses but lower revenue year over year. Revenue was $54.9 million, down from $66.8 million a year earlier, with a gross margin of 51%.
Net loss was $10.3 million, improving from $18.4 million in first quarter 2025 and $25.2 million in fourth quarter 2025. Adjusted EBITDA was a loss of $3.1 million, better than a $12.2 million loss a year ago and $10.3 million in fourth quarter 2025. Total visits reached 1.1 million.
For full year 2026, Amwell reaffirmed revenue guidance of $195–$205 million, AMG visits of 1.32–1.37 million, and updated adjusted EBITDA guidance to a loss of $16–$12 million. For second quarter 2026, it expects revenue of $48–$52 million and adjusted EBITDA of a $4–$2 million loss, and continues to target positive cash flow from operations in the fourth quarter of 2026.
American Well Corporation (Amwell) is asking stockholders to vote at its 2026 virtual annual meeting on electing two Class III directors, ratifying PricewaterhouseCoopers LLP as auditor for 2026, and approving executive pay on an advisory basis. The proxy also reviews 2025 performance, highlighting a shift to a tech‑enabled care platform and stronger operating discipline. Amwell recorded 2025 total revenue of $249.3 million, including $132.4 million of subscription revenue and $94.3 million of AMG visit revenue, with a 53% gross margin. Net loss narrowed to ($95.0) million from ($212.6) million in 2024, and total visits reached 4.5 million. Year‑end cash and short‑term securities were about $182.3 million. Management reiterates a goal of achieving positive operating cash flow in 2026 and emphasizes its Defense Health Agency SaaS deployment, AI‑enabled programs, and corporate responsibility initiatives. The Board remains majority‑independent and classified, and Amwell is a NYSE “controlled company” through Class B voting shares held by its co‑founders.
American Well Corp executive Phyllis Gotlib, President, International, reported an automatic sale of 3,706 shares of Class A Common Stock on April 1, 2026 at $5.30 per share. The sale was a non-discretionary “sell to cover” to pay taxes on vested restricted stock units.
After this transaction, Gotlib holds 163,004 shares directly and 114,250 shares indirectly through her husband, indicating the sale was small relative to her overall position and primarily for tax obligations rather than portfolio rebalancing.